These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15848527

  • 1. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.
    Baczkowska T, Perkowska-Ptasińska A, Sadowska A, Lewandowski Z, Nowacka-Cieciura E, Cieciura T, Pazik J, Lewandowska D, Mroz A, Urbanowicz A, Nazarewski S, Danielewicz R.
    Transplant Proc; 2005 Mar; 37(2):773-5. PubMed ID: 15848527
    [Abstract] [Full Text] [Related]

  • 2. The role of the protocol biopsies in renal allograft recipients.
    Baczkowska T, Perkowska-Francka A, Durlik M, Cieciura T, Nowacka-Cieciura E, Pazik J, Lewandowska D, Mroz A, Matlosz B, Chmura A, Galazka Z, Lao M.
    Transplant Proc; 2003 Sep; 35(6):2179-81. PubMed ID: 14529881
    [Abstract] [Full Text] [Related]

  • 3. Molecular and structural consequences of early renal allograft injury.
    Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA.
    Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
    [Abstract] [Full Text] [Related]

  • 4. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J, Arns W, Marti HP, Hauss J, Ketteler M, Beckurts T, Boesmueller C, Pohanka E, Martin PY, Gerhardt M, Farese S, Neumayer HH, Floege J, Gurr C, Budde K, DACH Study Group.
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis.
    Kaminska D, Tyran B, Mazanowska O, Letachowicz W, Kochman A, Rabczynski J, Szyber P, Patrzalek D, Chudoba P, Klinger M.
    Transplant Proc; 2005 Mar; 37(2):770-2. PubMed ID: 15848526
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
    Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M.
    Am J Transplant; 2007 Mar; 7(3):560-70. PubMed ID: 17229079
    [Abstract] [Full Text] [Related]

  • 7. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.
    Hueso M, Bover J, Serón D, Gil-Vernet S, Sabaté I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyó JM.
    Transplantation; 1998 Dec 27; 66(12):1727-31. PubMed ID: 9884267
    [Abstract] [Full Text] [Related]

  • 8. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun 27; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 9. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 10. TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy.
    Viklický O, Matl I, Voska L, Böhmová R, Jaresová M, Lácha J, Lodererová A, Stríz I, Teplan V, Vítko S.
    Physiol Res; 2003 Jul 15; 52(3):353-60. PubMed ID: 12790768
    [Abstract] [Full Text] [Related]

  • 11. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF, Gonçalves RT, Leite M, Santos MA, Delgado AG, Cardoso LR, Takiya CM.
    Nephrology (Carlton); 2015 Mar 15; 20(3):168-76. PubMed ID: 25404086
    [Abstract] [Full Text] [Related]

  • 12. A longitudinal study of TGF-beta1 protein levels in renal allograft recipients converted from CsA to MMF or AZA.
    van der Mast BJ, van Besouw NM, de Kuiper P, Vaessen LM, IJzermans JN, van Gelder T, Weimar W.
    Clin Transplant; 2000 Feb 15; 14(1):66-9. PubMed ID: 10693638
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C.
    J Am Soc Nephrol; 2005 Aug 15; 16(8):2509-16. PubMed ID: 15987748
    [Abstract] [Full Text] [Related]

  • 14. Modifying cyclosporine associated renal allograft dysfunction.
    Mohapatra N, Vanikar AV, Patel RD, Trivedi HL.
    Saudi J Kidney Dis Transpl; 2009 Sep 15; 20(5):770-4. PubMed ID: 19736471
    [Abstract] [Full Text] [Related]

  • 15. The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways.
    Gao R, Lu Y, Xin YP, Zhang XH, Wang J, Li YP.
    Transplant Proc; 2006 Sep 15; 38(7):2154-7. PubMed ID: 16980029
    [Abstract] [Full Text] [Related]

  • 16. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug 15; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction.
    Cantarovich M, Tzimas GN, Barkun J, Deschênes M, Alpert E, Tchervenkov J.
    Transplantation; 2003 Jul 15; 76(1):98-102. PubMed ID: 12865793
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
    Ruggenenti P, Perico N, Gotti E, Cravedi P, D'Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G.
    Transplantation; 2007 Oct 27; 84(8):956-64. PubMed ID: 17989600
    [Abstract] [Full Text] [Related]

  • 19. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
    Yang CW, Ahn HJ, Kim WY, Li C, Kim HW, Choi BS, Cha JH, Kim YS, Kim J, Bang BK.
    Kidney Int; 2002 Jul 20; 62(1):20-30. PubMed ID: 12081560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.